French national diagnostic and care protocol for Kawasaki disease
Copyright © 2023. Published by Elsevier Masson SAS..
Kawasaki disease (KD) is an acute vasculitis with a particular tropism for the coronary arteries. KD mainly affects male children between 6 months and 5 years of age. The diagnosis is clinical, based on the international American Heart Association criteria. It should be systematically considered in children with a fever, either of 5 days or more, or of 3 days if all other criteria are present. It is important to note that most children present with marked irritability and may have digestive signs. Although the biological inflammatory response is not specific, it is of great value for the diagnosis. Because of the difficulty of recognising incomplete or atypical forms of KD, and the need for urgent treatment, the child should be referred to a paediatric hospital as soon as the diagnosis is suspected. In the event of signs of heart failure (pallor, tachycardia, polypnea, sweating, hepatomegaly, unstable blood pressure), medical transfer to an intensive care unit (ICU) is essential. The standard treatment is an infusion of IVIG combined with aspirin (before 10 days of fever, and for a minimum of 6 weeks), which reduces the risk of coronary aneurysms. In case of coronary involvement, antiplatelet therapy can be maintained for life. In case of a giant aneurysm, anticoagulant treatment is added to the antiplatelet agent. The prognosis of KD is generally good and most children recover without sequelae. The prognosis in children with initial coronary involvement depends on the progression of the cardiac anomalies, which are monitored during careful specialised cardiological follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
La Revue de medecine interne - 44(2023), 7 vom: 19. Juli, Seite 354-380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galeotti, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aspirin |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 03.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.revmed.2023.06.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358506433 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358506433 | ||
| 003 | DE-627 | ||
| 005 | 20231226074903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.revmed.2023.06.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358506433 | ||
| 035 | |a (NLM)37349225 | ||
| 035 | |a (PII)S0248-8663(23)00647-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galeotti, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a French national diagnostic and care protocol for Kawasaki disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Masson SAS. | ||
| 520 | |a Kawasaki disease (KD) is an acute vasculitis with a particular tropism for the coronary arteries. KD mainly affects male children between 6 months and 5 years of age. The diagnosis is clinical, based on the international American Heart Association criteria. It should be systematically considered in children with a fever, either of 5 days or more, or of 3 days if all other criteria are present. It is important to note that most children present with marked irritability and may have digestive signs. Although the biological inflammatory response is not specific, it is of great value for the diagnosis. Because of the difficulty of recognising incomplete or atypical forms of KD, and the need for urgent treatment, the child should be referred to a paediatric hospital as soon as the diagnosis is suspected. In the event of signs of heart failure (pallor, tachycardia, polypnea, sweating, hepatomegaly, unstable blood pressure), medical transfer to an intensive care unit (ICU) is essential. The standard treatment is an infusion of IVIG combined with aspirin (before 10 days of fever, and for a minimum of 6 weeks), which reduces the risk of coronary aneurysms. In case of coronary involvement, antiplatelet therapy can be maintained for life. In case of a giant aneurysm, anticoagulant treatment is added to the antiplatelet agent. The prognosis of KD is generally good and most children recover without sequelae. The prognosis in children with initial coronary involvement depends on the progression of the cardiac anomalies, which are monitored during careful specialised cardiological follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Diagnostic | |
| 650 | 4 | |a Follow-up | |
| 650 | 4 | |a Kawasaki disease | |
| 650 | 4 | |a Maladie de Kawasaki | |
| 650 | 4 | |a Suivi | |
| 650 | 4 | |a Traitement | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Bajolle, F |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, A |e verfasserin |4 aut | |
| 700 | 1 | |a Biscardi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bosdure, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bourrat, E |e verfasserin |4 aut | |
| 700 | 1 | |a Cimaz, R |e verfasserin |4 aut | |
| 700 | 1 | |a Darbon, R |e verfasserin |4 aut | |
| 700 | 1 | |a Dusser, P |e verfasserin |4 aut | |
| 700 | 1 | |a Fain, O |e verfasserin |4 aut | |
| 700 | 1 | |a Hentgen, V |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, V |e verfasserin |4 aut | |
| 700 | 1 | |a Lefevre-Utile, A |e verfasserin |4 aut | |
| 700 | 1 | |a Marsaud, C |e verfasserin |4 aut | |
| 700 | 1 | |a Meinzer, U |e verfasserin |4 aut | |
| 700 | 1 | |a Morin, L |e verfasserin |4 aut | |
| 700 | 1 | |a Piram, M |e verfasserin |4 aut | |
| 700 | 1 | |a Richer, O |e verfasserin |4 aut | |
| 700 | 1 | |a Stephan, J-L |e verfasserin |4 aut | |
| 700 | 1 | |a Urbina, D |e verfasserin |4 aut | |
| 700 | 1 | |a Kone-Paut, I |e verfasserin |4 aut | |
| 700 | 0 | |a collaborators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue de medecine interne |d 1983 |g 44(2023), 7 vom: 19. Juli, Seite 354-380 |w (DE-627)NLM012660108 |x 1768-3122 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:7 |g day:19 |g month:07 |g pages:354-380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.revmed.2023.06.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 7 |b 19 |c 07 |h 354-380 | ||